Clinical Trials
11 trialsNCT07015242 2026-03-24
A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 2 Recruiting
NCT03495960 2025-01-30
FIORELLA
International Extranodal Lymphoma Study Group (IELSG)
Phase 2 Completed
NCT04514393 2022-04-07
Ibrutinib With Methotrexate and Temozolomide for Patients With Newly Diagnosed Primary CNS Lymphoma
Sun Yat-sen University
Phase 2 Unknown
NCT01235793 2018-11-20
DRBEAT
Cedars-Sinai Medical Center
Phase 2 Terminated
NCT00248534 2018-09-04
Rituximab, Temozolomide, and Methylprednisolone in Treating Patients With Recurrent Primary CNS Non-Hodgkin's Lymphoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Terminated
NCT02113007 2017-02-07
Study of High-Dose Rituximab With Temozolomide as Treatment for Primary Central Nervous System (CNS) Lymphoma
SCRI Development Innovations, LLC
Phase 2 Terminated
NCT00098774 2016-07-06
Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Primary CNS Lymphoma
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT01985451 2013-11-15
Pemetrexed and Temozolomide in Treating Patients With Relapsed Primary Central Nervous System Lymphoma （PCNSL）
Shandong Cancer Hospital and Institute
Phase 2 Unknown
NCT01735747 2013-03-12
Temozolomide, Nedaplatin, Vincristine, and Radiotherapy as First-line Treatment in Newly Diagnosed Primary CNS Lymphoma
Shandong Cancer Hospital and Institute
Phase 2 Unknown
NCT00503594 2012-07-30
CNSLymphoma
Assistance Publique - Hôpitaux de Paris
Phase 2 Unknown
NCT00004106 2012-06-06
Temozolomide in Treating Patients With Mycosis Fungoides or Sezary Syndrome
Northwestern University
Phase 2 Terminated